Article Text

Download PDFPDF
Details on hormone replacement therapy
  1. Felice L Gersh1,
  2. Carl J Lavie2
  1. 1 College of Medicine, University of Arizona, Tucson, Arizona, USA
  2. 2 Cardiology, John Ochsner Heart and Vascular Institute, New Orleans, Louisiana, USA
  1. Correspondence to Dr Carl J Lavie, Cardiology, John Ochsner Heart and Vascular Institute, New Orleans, LA 70121, USA; clavie{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The Authors’ reply:

We greatly appreciate the interest in our editorial1 from Scarabin and colleagues. We find it encouraging that voices from around the world are enthusiastically endorsing the appropriate use of human-identical hormones while also displaying a deep understanding of the physiological impacts that differentiate the substances used in the Women’s Health Initiative study from hormones that naturally exist in a female body. As our French colleagues noted, we emphasised the importance of using physiological human-identical transdermal estradiol, combined with natural progesterone. We also referenced the …

View Full Text


  • Contributors Both FG and CL contributed equally to this response.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles